文献速递膀胱癌与上尿路尿路上皮癌

HER2表达在接受卡介苗暴露的非肌层浸润性膀胱癌患者中的预后意义

Prognostic Significance of HER2 Expression in Patients with Bacillus Calmette-Guérin-exposed Non-muscle-invasive Bladder Cancer.
PubMed 文献 · Eur Urol Oncol · 2023-10-24

本研究纳入454例非肌层浸润性膀胱癌患者,均接受BCG膀胱灌注(1.2×10^8 CFU,菌株D2PB302),其中314例有HER2免疫组化结果。HER2过表达(IHC评分2/3+)占35.7%,该组5年无复发生存率仅16.5%,显著低于HER2低表达组的68.0%(p<0.001)。结论认为HER2是不良BCG疗效的独立预测因子,高危且HER2过表达患者复发进展风险最高。

要点

  • HER2过表达(IHC 2/3+)占35.7%,5年无复发生存率16.5%,低于低表达组的68.0%(p<0.001)。
  • 高危NMIBC且HER2过表达者5年无复发生存率和无进展生存率分别为19.0%和58.2%。
  • 高危NMIBC且HER2阴性(IHC 0)者5年无复发生存率和无进展生存率分别为80.8%和92.1%。

核心结论

  • HER2是非肌层浸润性膀胱癌中BCG疗效不佳的独立预测因子。
  • 高危NMIBC且HER2过表达患者在接受BCG暴露后疾病复发和进展风险最高。
  • 作者认为可考虑对这些患者采用抗HER2靶向治疗。

研究设计与样本

  • 纳入454例非肌层浸润性膀胱癌患者,所有患者在经尿道膀胱肿瘤电切术后2-6周开始BCG膀胱灌注(1.2×10^8 CFU,菌株D2PB302),1年内共接受19次治疗。
  • 314例患者有HER2免疫组化结果。
  • 采用多变量Cox回归和log-rank分析探索结局关系。

主要发现

  • 在免疫组化人群中,35.7%的患者HER2过表达(IHC评分2/3+)。
  • HER2过表达组5年无复发生存率为16.5%,HER2低表达组为68.0%(p<0.001)。
  • 高危NMIBC且HER2过表达患者5年无复发生存率和无进展生存率分别为19.0%和58.2%。
  • 高危NMIBC且HER2阴性(IHC评分0)患者5年无复发生存率和无进展生存率分别为80.8%和92.1%。

临床怎么用

  • 作者认为,对于高危NMIBC且HER2过表达的患者,可考虑抗HER2靶向治疗。
  • 患者摘要指出,检测HER2蛋白水平可用于预测中危和高危NMIBC患者接受BCG膀胱治疗后的结局,可能有助于指导个性化治疗。

局限性

  • 局限性包括回顾性研究设计。
  • 关于BCG使用的详细信息有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Guidelines recommend intravesical instillation of bacillus Calmette-Guérin (BCG) as the first-choice treatment for intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC). However, there is no therapeutic biomarker for predicting BCG efficacy, especially in high-risk cases with high failure rates. HER2 expression is considered a prognostic factor for bladder cancer. OBJECTIVE: To elucidate the predictive value and significance of HER2 expression in patients with BCG-exposed NMIBC. DESIGN, SETTING, AND PARTICIPANTS: A total of 454 patients with NMIBC were included. All patients started BCG intravesical instillation (1.2 × 108 CFU, strain D2PB302) 2-6 wk after transurethral resection of bladder tumor and received 19 treatments over a period of 1 yr. HER2 immunohistochemistry (IHC) results available for 314 patients. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The outcomes investigated were recurrence-free survival (RFS) and progression-free survival (PFS). Outcome relationships were explored using multivariable Cox regression and log-rank analysis. RESULTS AND LIMITATIONS: In the IHC population, 35.7% of patients had HER2 overexpression (IHC score 2/3+). This group had a poor 5-yr RFS rate of 16.5%, in comparison to 68.0% in the group with low HER2 expression (p < 0.001). Patients with high-risk NMIBC and HER2 overexpression had the highest risk of BCG treatment failure, with 5-yr RFS and PFS rates of 19.0% and 58.2%, respectively. Conversely, HER2-negative (IHC score 0) patients with high-risk NMIBC experienced a long-term BCG benefit, with 5-yr RFS and PFS rates of 80.8% and 92.1%, respectively. Limitations include the retrospective study design and the limited details regarding BCG use. CONCLUSIONS: HER2 was an independent predictor of poor BCG efficacy in NMIBC. Patients with high-risk NMIBC and HER2 overexpression had the highest risk of disease recurrence and progression after exposure to BCG. Anti-HER2 targeted therapies could be considered for these patients. PATIENT SUMMARY: Measurement of blood levels of the protein HER2 can be used to predict outcomes after BCG (bacillus Calmette-Guérin) bladder therapy for patients with intermediate- or high-risk non-muscle-invasive bladder cancer. Measurement results for HER2 may help in guiding personalized treatment for these patients.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Tan X, Liu Z, Cai T, et al. Prognostic Significance of HER2 Expression in Patients with Bacillus Calmette-Guérin-exposed Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. 2023. PMID: 37884420. doi:10.1016/j.euo.2023.10.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。